IRVINE, Calif.--(BUSINESS WIRE)--Jan. 9, 2006--Xytis Inc. ("Xytis") announced today that it has raised a $24.5 million Series B financing round, which will be used to develop proprietary small molecules and novel allosteric modulators in preclinical and clinical (Phase I and Phase II) stages for the treatment of Central Nervous System disorders addressing unmet medical needs within large markets. The financing was led by Sanderling Ventures, together with Atlas Venture, Ventech and CDC Entreprises Innovation.
